On January 4, Aurobindo Pharma saw a slight loss amid a weaker market. As of 12:01 pm, Aurobindo Pharma was trading at ₹ 440.20, down Re 1, or 0.23%, on the BSE. It reached an intraday high of ₹ 445 and an intraday low of ₹ 440.10.
In a BSE filing, the company announced that its subsidiary Eugia Pharma Specialties Limited received final approval from the US Food and Drug Administration to produce and sell azacitidine for injection in 100 mg single-dose vials.
Azacitidine for injection in 100 mg single-dose vials has been deemed bioequivalent and therapeutically equivalent to Bristol-Myers Squibb’s Vidaza for injection in 100 mg single-dose vials, which is the reference listed drug for this product. The launch of this product is anticipated for this month, and according to IQVIA, the market size for it is estimated to be around $46 million for the 12 months ending November 2022.
This marks the 153rd ANDA (including 10 tentative approvals) for the Eugia Pharma Specialty Group facility, which produces oral and sterile specialty products,” the company added.
For More Latest News Click Here